Vaccentis has dedicated itself to the development and production of autologous tumour vaccines.
With VCC-001, the company already has a promising product candidate for adjuvant renal cell carcinoma in development, which has achieved clinical efficacy and a good safety and tolerability profile in various clinical trials.
